Document is current
Any future updates will be listed below
-
Authors
Jin, Jia xiang https://orcid.org/0000-0001-6574-7816
Besemer, Britta
Yilmaz, Büsranur
Hänel, Mathias
Fenk, Roland
Bertsch, Uta
Gu, Kaarina-Jiayuan
Hanoun, Christine
Blau, Igor W.
Mann, Christoph
Scheid, Christof
Schroers, Roland
von Metzler, Ivana
Hensel, Manfred
Klein, Eva-Maria
Hoffmann, Martin
Lutz, Christoph
Riesenberg, Hendrik
Martens, Uwe M. https://orcid.org/0000-0001-7999-4359
Michel, Christian S. https://orcid.org/0009-0004-1596-3763
Kunz, Christian
Shumilov, Evgenii
Gezer, Deniz
Holderried, Tobias A. W. https://orcid.org/0000-0002-2474-523X
Trautmann-Grill, Karolin https://orcid.org/0000-0002-9050-1049
Müller-Tidow, Carsten https://orcid.org/0000-0002-7166-5232
Weisel, Katja C. https://orcid.org/0000-0001-9422-6614
Raab, Marc S. https://orcid.org/0000-0003-4181-6922
Salwender, Hans J. https://orcid.org/0000-0001-7803-0814
Goldschmidt, Hartmut https://orcid.org/0000-0003-0961-0035
Mai, Elias K. https://orcid.org/0000-0002-6226-1252
-
Funding
Funding for this research was provided by:
Dietmar Hopp Stiftung (1DH1811373)
- License Information
-
More Information
Article History
Received: 2 July 2025
Revised: 2 September 2025
Accepted: 18 September 2025
First Online: 20 October 2025
Competing interests
: Mathias Hänel: Honoraria: Kite/Gilead, Falk Foundation, Sobi, BMS; Consulting or Advisory role: Janssen, Kite/Gilead, Amgen, Sanofi, BMS, BeiGene, Sobi. Britta Besemer: Consulting or Advisory: Janssen-Cilag, Honoraria: GSK, AMGEN, Sanofi, Takeda, Pfizer, Oncopeptides. Hans J. Salwender: Honoraria: Janssen, BMS GmbH & Co KG, Amgen, AbbVie, Stemline Therapeutics, Oncopeptides, AstraZeneca, Sanofi, Genzyme, GlaxoSmithKline, Pfizer, Roche; Consulting or Advisory Role: Pfizer, Janssen Oncology, Sanofi, Oncopeptides, GlaxoSmithKline, Amgen, AbbVie, Bristol Myers Squibb/ Celgene, Roche, Genzyme, Stemline Therapeutics, AstraZeneca; Travel accommodations and expenses: Amgen, BMS GmbH & Co KG, Janssen, Pfizer, Stemline Therapeutics, Sanof. Roland Schroers: BMS, Janssen, Gilead, Oncopeptides, Stemline. Marc S. Raab: BMS, AMGEN, GSK, Janssen, Sanofi, Pfizer, Takeda, AbbVie, Heidelberg Pharma, Oncopeptides. Ivana von Metzler: Honoraria for advising Pfizer, Sanofi, BMS, GSK, Amgen, Janssen, Takeda, Oncopeptides, Stemline and AstraZeneca. Uwe M Martens: Advisory boards: AstrZeneca, Astellas, MDS, Roche, BMS, Takeda, Travel support: BeiGene, IPSEN, Lilly, Pierre Fabre. Karolin Trautmann-Grill: AMGEN, GSK, Sanofi, Stemline, Takeda. Katja C. Weisel: Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, BMS, BeiGene, Cellcentric, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline, Takeda. Hartmut Goldschmidt: Grants and/or provision of Investigational Medicinal Product: BMS/Celgene, Dietmar Hopp Foundation, Janssen, Sanofi. Research Support: Amgen, BMS, Celgene, GlycoMimetics Inc., GlaxoSmithKline (GSK), Heidelberg Pharma, Hoffmann-La Roche, Janssen Research and Development, Millenium, Novartis, Pfizer, Sanofi. Advisory Boards: BMS, Janssen, Sanofi, GlaxoSmithKline (GSK). Honoraria / Secondary employment: Amgen, BMS, GlaxoSmithKline (GSK), Janssen, Sanofi, Pfizer, Oncopeptides. Support for attending meetings and/or travel: Amgen, BMS, GlaxoSmithKline (GSK), Janssen, Sanofi, Pfizer, Oncopeptides. Elias K. Mai: Advisory Board: Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini Stemline, Oncopeptides, Pfizer, Sanofi und Takeda; Honoraria: Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini Stemline, Oncopeptides, Pfizer, Sanofi und Takeda; Research funding: Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi und Takeda; Travel expenses: Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini Stemline, Pfizer, Sanofi und Takeda. All authors other than those above have no conflicts of interest to declare.
